Edition:
United States

OncoSec Medical Inc (ONCS.OQ)

ONCS.OQ on NASDAQ Stock Exchange Capital Market

1.73USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$1.73
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
314,834
52-wk High
$2.95
52-wk Low
$0.88

Chart for

About

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid... (more)

Overall

Beta: 3.27
Market Cap(Mil.): $61.27
Shares Outstanding(Mil.): 35.42
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 186.11 15.67
EPS (TTM): -- -- --
ROI: -- -11.32 34.62
ROE: -- -35.69 16.00

BRIEF-OncoSec Medical files for offering of up to 6.83 mln shares

* OncoSec Medical Inc files for offering of up to 6.83 million shares of co's common stock by the selling shareholders - SEC filing Source: (http://bit.ly/2hEfpJ6) Further company coverage:

Nov 16 2017

BRIEF-Oncosec announces positive follow-up data from phase 2 trial of Immunopulse il-12

* Oncosec announces positive updated long-term follow-up data from phase 2 trial of Immunopulse il-12 in combination with pembrolizumab demonstrating a progression free survival rate (PFS) of 57% at 15 months in predicted anti-pd-1 non-responder melanoma p Source text for Eikon: Further company coverage:

Nov 08 2017

BRIEF-Oncosec appoints Daniel O'Connor as CEO

* Oncosec appoints Daniel J. O'Connor as chief executive officer to lead next stage of growth as a fully integrated late stage development and commercial company

Nov 07 2017

BRIEF-Intracoastal Capital LLC reports 7.5 pct passive stake in OncoSec Medical

* Intracoastal Capital LLC reports 7.5 pct passive stake in OncoSec Medical Inc, as of October 22, 2017‍​ Source text: [http://bit.ly/2zVkxvZ] Further company coverage:

Oct 31 2017

BRIEF-OncoSec Q4 loss per share $0.28

* OncoSec announces fourth quarter and year end financial results for fiscal year 2017

Oct 25 2017

BRIEF-ONCOSEC ANNOUNCES $7.1 MLN REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET

* ONCOSEC ANNOUNCES $7.1 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET

Oct 23 2017

BRIEF-Oncosec presents positive Phase 2 data for immunopulse® IL-12 in combination with Pembrolizumab

* Oncosec presents positive Phase 2 data for Immunopulse® IL-12 in combination with Pembrolizumab demonstrating a best overall response rate (BORR) of 50 pct in predicted anti-PD-1 non-responder melanoma patients

Oct 19 2017

BRIEF-OncoSec appoints industry veteran Annalisa Jenkins MBBS, FRCP to board of directors

* OncoSec appoints industry veteran Annalisa Jenkins MBBS, FRCP to board of directors Source text for Eikon: Further company coverage:

Sep 05 2017

Earnings vs. Estimates